<DOC>
	<DOCNO>NCT00493623</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety intravenous Bonviva patient osteoporosis experience pain recent vertebral osteoporotic fracture . Patients randomize receive either Bonviva ( 3mg i.v . bolus injection ) placebo . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>BONDIR Study : A Study Intravenous Bonviva ( Ibandronate ) After Recent Vertebral Osteoporotic Fracture Patients With Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporotic Fractures</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>postmenopausal woman men &gt; 30 year age ; osteoporosis ; vertebral osteoporotic fracture past 4 week ; fracturerelated pain require analgesic treatment . nonmenopausal woman ; current treatment another bisphosphonate ; current treatment class III analgesic .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>